Ramesh Eluri, MD
Psychiatry · Philadelphia, PANPI 1497706097
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,335 of the $84,891 with a category attached, or 64.0%. 32 manufacturers reported payments, led by AbbVie at 34.8% of the total. Reporting peaked in 2023 at $32,187 and has fallen 67.5% since, to $10,448 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 711 payments — averaging $119.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Alkermes, Inc.$18K
- Supernus Pharmaceuticals, Inc.$12K
- E.r. Squibb & Sons, L.L.C.$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- plus $8K from 26 others
What the payments were for
- Consulting fees$11,02313%
- Speaking & faculty fees$54,33564%
- Travel & lodging$5,3326%
- Food & beverage$13,98516%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 143 | $29,533 |
| Alkermes, Inc. | 77 | $18,416 |
| Supernus Pharmaceuticals, Inc. | 39 | $11,731 |
| E.r. Squibb & Sons, L.L.C. | 21 | $8,386 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $5,621 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $3,088 |
| Otsuka America Pharmaceutical, Inc. | 78 | $1,893 |
| Johnson & Johnson | 67 | $1,321 |
| Lundbeck LLC | 41 | $592 |
| Vanda Pharmaceuticals Inc. | 24 | $572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $554 |
| Neurocrine Biosciences, Inc. | 22 | $535 |
| Teva Pharmaceuticals USA, Inc. | 24 | $505 |
| Axsome Therapeutics, Inc. | 21 | $462 |
| Sunovion Pharmaceuticals Inc. | 14 | $241 |
| Indivior Inc. | 9 | $190 |
| Jazz Pharmaceuticals Inc. | 7 | $147 |
| Corium, LLC | 5 | $109 |
| Shire North American Group Inc | 7 | $104 |
| Tris Pharma Inc | 6 | $102 |
| Adlon Therapeutics L.p. | 5 | $91 |
| Avanir Pharmaceuticals, Inc. | 6 | $89 |
| Evoke Pharma, Inc. | 1 | $85 |
| Bausch Health US, LLC | 5 | $83 |
| Harmony Biosciences LLC | 3 | $82 |
| Braeburn Inc. | 3 | $78 |
| Ironshore Pharmaceuticals Inc. | 3 | $71 |
| Orexo US, Inc. | 4 | $51 |
| Collegium Pharmaceutical, Inc. | 3 | $51 |
| Neos Therapeutics, LP | 2 | $48 |
| Neuronetics, Inc. | 2 | $31 |
| OWP Pharmaceuticals, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$67,929
- VRAYLAR$27,791
- ARISTADA INITIO$16,982
- QELBREE$9,000
- CAPLYTA$2,400
- COBENFY$1,632
- REXULTI$348
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
How this compares
$84,891 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 95 | $12,037 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,250 |
| Buprenorphine Hcl | 40 | $1,789 |
| Quetiapine Fumarate | 71 | $1,404 |
| Bupropion XlBupropion Hcl | 39 | $1,025 |
| Aripiprazole | 31 | $919 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $903 |
| Fluoxetine Hcl | 19 | $823 |
| Olanzapine | 24 | $679 |
| Doxepin Hcl | 29 | $551 |
| Buspirone Hcl | 22 | $486 |
| Clonazepam | 83 | $462 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $442 |
| Gabapentin | 11 | $410 |
| Duloxetine Hcl | 34 | $396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $554 | $5,25011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.